Shawn Tomasello has extensive strategic experience in building world class organizations encompassing commercial, compliance, regulatory, pricing and medical affairs functions. From 2015 to 2018, Ms. Tomasello served as the Chief Commercial Officer of Kite Pharma, where she oversaw the global commercialization of the CAR T-cell therapy Yescarta® and played a key role in the company’s acquisition by Gilead Sciences. She previously served as Chief Commercial Officer of Pharmacyclics, where she led both commercial and medical affairs. Prior to Pharmacyclics, Ms. Tomasello served as President of the Americas, Hematology and Oncology at Celgene, where she led the company through five successful product launches encompassing 11 indications and played a critical role in acquisitions. She currently serves on the boards of TCR2 Therapeutics, 4D Molecular Therapeutics, UroGen Pharma, Mesoblast, Gamida Cell and Centrexion Therapeutics. Ms. Tomasello received her BS in Marketing from the University of Cincinnati and her MBA from Murray State University in Kentucky.
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?